Agilus Diagnostics IPO Details

MAINBOARD

Agilus Diagnostics IPO DRHP (Draft Red Herring Prospectus) has been Filed With SEBI.

Pre-issue shareholding stands at 7,84,25,542, which will increase to 7,84,25,542 post-issue.

The Lead Managers for Agilus Diagnostics IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Axis Capital Limited, ICICI Securities Limited, Citigroup Global Markets India Private Limited. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.

For detailed information, Refer to the Agilus Diagnostics Limited DRHP.

Agilus Diagnostics IPO Details

Open Date
-
Close Date
-
Listing Date
-
Issue Price
₹0 - ₹0
Face Value
₹10 per share
Lot Size
0
GMP
₹0
Issue Type
IPO
Listing On
NSE, BSE
Type
Book Built Issue
Share holding pre issue
78425542
Share holding post issue
78425542
Total Issue Size
-
Fresh Issue
-
Offer for Sale
-
DRHP Status
Filed With SEBI

Agilus Diagnostics IPO Lot Size

ApplicationLotsSharesAmount
To be announced

Agilus Diagnostics IPO Reservation

Promoter Holding

Pre Issue:57.68%
Post Issue:-
Promoter Names:
Fortis Healthcare Limited

Documents

Agilus Diagnostics IPO Valuations

To be announced

Agilus Diagnostics Financial Information

Period Ended31 Mar 202331 Mar 202231 Mar 2021
Assets2,418.742,279.961,586.31
Total Income1,371.101,618.351,060.69
Profit After Tax116.64554.71131.25
Net Worth1,945.581,866.151,311.38
Reserves and Surplus1,867.151,787.731,232.96
Total Borrowing1.252.252.83
Amount in ₹ Crore

About Agilus Diagnostics IPO

Agilus Diagnostics Limited, incorporated in 1995, provides diagnostic testing services, including routine and specialized tests, wellness and preventive care packages, hospital laboratory management services, and clinical research trial testing services.

As of March 31, 2023, the company operated a network of 413 laboratories, with 43 laboratories accredited by the National Accreditation Board for Testing and Calibration Laboratories (NABL).

Agilus Diagnostics Limited maintains an international presence across regions including the Middle East, Sub-Saharan Africa, the Commonwealth of Independent States, and the South Asian Association for Regional Cooperation (SAARC).

During the fiscal year 2023, the company conducted 39.07 million tests and served 16.62 million patients in India and internationally.

The diagnostics network spans 25 Indian states and five union territories, covering over 1,000 towns and cities and more than 532 districts. The network follows a hub-and-spoke model and includes one central global reference laboratory in Mumbai, five regional reference laboratories, and 407 other clinical laboratories, comprising pathology and radiology centers.

Agilus Diagnostics Limited also operates 25 wellness centers, three Centers of Excellence, 3,757 customer touch points such as patient service centers and collection centers, and over 12,000 pick-up points serving institutional clients.

The test portfolio consists of over 3,600 routine and specialized diagnostic tests and wellness packages across various medical specialties.

The company provides services to both individual patients (B2C) through walk-in centers, home collection services in over 80 cities, and digital platforms, and institutional customers (B2B), including physician offices, hospitals, laboratories, radiology centers, corporate employers, insurance companies, public-private partnerships, and clinical research organizations.

As of March 31, 2023, we had a total of 7,061 employees, including 438 doctors, 4,176 technicians and paramedical staff and 2,447 support staff located in India, and 84 full-time employees located outside India.

Competitve Strenghts:

  • Experienced pan-India diagnostics service provider with a diversified presence and a growing network that is well positioned to capitalize on the expected growth in the Indian diagnostics industry.
  • Comprehensive test offerings providing one stop solution for diagnostic requirements.
  • Advanced information technology platform supported by integrated systems enabling customer-centric initiatives.
  • Well-balanced B2C and B2B revenue mix.
  • Quality network of accredited laboratories supported by R&D capabilities focused on genomics and next-generation diagnostics.
  • Strong parentage and experienced management team with significant industry experience.

Strength Of Agilus Diagnostics IPO

To be announced

Risk Of Agilus Diagnostics IPO

To be announced

Objectives Agilus Diagnostics IPO

To be announced

Company Contact Details

Agilus Diagnostics Ltd.
Fortis Hospital,
Sector 62,
Phase – VIII,
Mohali, Punjab, 160062
Phone: 0124-6261111
Email: investors@agilus.in
Website: http://www.agilusdiagnostics.com/

Registrar Contact Details

Name: Kfin Technologies Limited
Phone: +91-40-67162222

Comments